Hormonal
Weekly subcutaneous semaglutide (2.4 mg) and tirzepatide (up to 15 mg) produce significantly greater mean weight loss (12-21%) in non-diabetic obese adults compared to daily liraglutide (3 mg, 5-8%) or placebo.
If you have obesity and are not diabetic, newer weekly injections like semaglutide (2.4 mg) or tirzepatide (up to 15 mg) are significantly more effective for weight loss than older daily options like liraglutide. Expect 15-20% body weight loss in clinical trials. Be prepared for gastrointestinal side effects, which usually improve over time. Crucially, stopping the medication typically leads to significant weight regain, suggesting long-term use may be necessary for sustained results.
In the 68-week STEP 8 trial, a statistically significant reduction in body weight was observed, with a mean percentage change of –15.8% for once-weekly semaglutide 2.4 mg and –6.4% for once-daily liraglutide 3 mg. In the 72-week SURMOUNT 1 trial, tirzepatide resulted in mean weight change of −15.0%, −19.5%, and −20.9% with weekly doses of 5 mg, 10 mg, and 15 mg, respectively, compared to −3.1% with placebo.
Why this rating
Based on multiple large-scale, randomized clinical trials (STEP 1, 3, 4, 8; SURMOUNT 1, 3) with statistically significant results.
Source
Incretin Analogues for Weight Reduction in Non-Diabetic Obese: A Review of Liraglutide, Semaglutide, and Tirzepatide Beyond Glycemic Control
Krishna Nikhila Bonga et al. · Rambam Maimonides Medical Journal · 2026
DOI 10.5041/rmmj.10565
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →